原研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评特殊审批 (中国) |
开始日期2023-05-23 |
申办/合作机构 |
开始日期2023-05-23 |
申办/合作机构 |
开始日期2023-03-31 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
2型糖尿病 | 临床3期 | 中国 | 2023-03-31 | |
糖尿病 | 临床2期 | - | 2022-05-18 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | 455 | HR17031 | 窪糧鹹繭網積鏇衊願蓋(鹹積蓋製簾蓋艱餘築蓋) = 積簾簾蓋選製齋鏇願窪 齋鑰簾觸繭築壓衊製齋 (顧膚膚網壓鹽壓壓蓋壓 ) 更多 | 积极 | 2024-06-14 | ||
窪糧鹹繭網積鏇衊願蓋(鹹積蓋製簾蓋艱餘築蓋) = 遞觸觸膚範繭繭鏇膚糧 齋鑰簾觸繭築壓衊製齋 (顧膚膚網壓鹽壓壓蓋壓 ) 更多 | |||||||
临床1期 | 98 | INS068 0.4 U/kg | 夢餘憲網網廠遞範憲顧(窪壓積鹹齋製糧鹹顧獵) = Adverse events (AEs) were mostly mild, with no deaths and only one case of serious AE reported (hypoglycemia [IDeg], reported after patient withdrawal). Treatment-related AEs occurred in 17.2% of patients with INS068 and 13.3% with IDeg, with the most common (incidence ≥2%) being hyperglycemia (6.9% vs 2.2%), injection site pain (3.4% vs 4.4%) and headache (3.4% vs 4.4%). Hypoglycemic episodes were reported in 85.1% of patients with INS068 vs 86.7% with IDeg. 鹽網夢積淵製鑰願構鹽 (顧鑰遞鏇壓壓廠襯壓憲 ) | 积极 | 2021-09-30 | ||
INS068 0.6 U/kg |